Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365427 | 0.94 | HDAC2 (0.42) | HDAC2HSD11B1LRRK2USP30MAP4K1 | |
| SCHEMBL17618515 | 0.94 | HDAC2 (0.42) | HDAC2HSD11B1LRRK2USP30MAP4K1 | |
| SCHEMBL17618441 | 0.93 | HDAC2 (0.42) | HDAC2GPR6HSD11B1LRRK2USP30 | |
| SCHEMBL19704835 | 0.89 | USP30 (0.43) | HSD11B1LRRK2USP30MAP4K1CPT2 | |
| SCHEMBL19706070 | 0.87 | LRRK2 (0.38) | HDAC2GPR6HSD11B1LRRK2MAP4K1 | |
| SCHEMBL19706069 | 0.85 | USP30 (0.39) | GPR6HSD11B1LRRK2USP30MAP4K1 | |
| SCHEMBL20633151 | 0.85 | LRRK2 (0.39) | HDAC2HSD11B1LRRK2USP30MAP4K1 | |
| SCHEMBL19706194 | 0.84 | THRB (0.41) | HSD11B1LRRK2USP30 | |
| SCHEMBL19670420 | 0.83 | HDAC2 (0.42) | HDAC2GPR6USP30 | |
| SCHEMBL17618391 | 0.83 | SCD (0.41) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HDAC2 50/4885GPR6 2629/4885HSD11B1 3528/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | HDAC2 50/4885GPR6 2629/4885HSD11B1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.